Microbot Medical Accelerates Patient Enrollment of its Pivotal Human Clinical Trial; Expects to Complete the Trial Earlier Than Anticipated as 80% of Patients Have Completed Follow up

Confirms the Company on Track for FDA 510(k) Submission by end of 2024

Completes All IDE required Tests and Receives Final IDE Approval from the FDA for the ACCESS-PVI Study